Skip to main content

Search

Reset all filters
329 Result(s)
Sort by

How BI Supports Grass Roots Innovation

How BI Supports Grass Roots Innovation

Hear from life-science entrepreneurs about how we are supporting early-stage science through our innovative Grass Roots program.
Combivent® Respimat®

Combivent® Respimat®

A combination of a short-acting anticholinergic and beta-adrenergic for the management of reversible bronchospasms associated with obstructive airway diseases in patients requiring more than one bronchodilator.
Rabisin® / Imrab®

Rabisin® / Imrab®

Rabisin® is used for the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection.
BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Rabisin® / Raboral V-RG®

Rabisin® / Raboral V-RG®

Rabisin® is used for the active immunisation of dogs and cats to reduce mortality and clinical signs due to rabies infection.
Recombitek®

Recombitek®

Recombitek® offers a complete line of canine vaccines against distemper, major circulating strains CPV-2a, 2b, 2c, prevention of disease and shedding against leptospirosis.
Glyxambi®

Glyxambi®

Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with both empagliflozin and linagliptin is appropriate (US).
Praxbind®

Praxbind®

Praxbind® is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa® (dabigatran etexilate) when rapid reversal of its anticoaculant effects is required: for emergency surgery/urgent procedures; in life-threa
BI_PharmAccess_launch_digital_healthcare_program

BI_PharmAccess_launch_digital_healthcare_program

Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management